The Asian Network of People who Use Drugs (ANPUD) and the International Network of People who Use Drugs (INPUD), through our national network allies and colleagues, are leading a global week of action against the extrajudicial killings of people who use drugs in the Philippines. The global week of action will take place in the week beginning October 10th 2016. The week will focus actions at embassies and consulates of the Philippines around the world. You are encouraged to take the lead in identifying an appropriate date in the week for a peaceful demonstration at embassies and consulates.
INPUD (the International Network of People who Use Drugs) and ANPUD (the Asian Network of People who Use Drugs) urgently request a halt be called on the killing of people who use drugs in the Philippines. We implore Your Excellency President Duterte to reconsider the current approach of executing people who use drugs in favour of internationally accepted, evidence-based alternatives.
Mr. Charanjit Sharma, from Manipur in North-East India, is the secretary of the Indian Drug Users Forum (IDUF). He is also involved with the India HIV/AIDS Alliance.
Being recently selected as a Civil Society Speaker out of 257 applicants, he, with his grassroot experiences, represented drug user community and addressed our issues at the United Nations General Assembly Special Session (UNGASS) on the World Drug Problem held during 19-21 April 2016 at the United Nations Headquarters in New York. He spoke in the 6th plenary along with 4 other Civil Society speakers from different parts of the world.
The verbatim script of his speech and video is published. Please go to time 2:28:50 to directly watch Mr. Charan’s speech.
Kenneth Sherman from the University of Cincinnati presented findings from the Phase 3 ALLY-2 trial, which evaluated Gilead Sciences’ nucleotide polymerase inhibitor sofosbuvir plus Bristol-Myers Squibb’s NS5A inhibitor daclatasvir without ribavirin.
Daclatasvir is available in Europe and Japan and is currently awaiting U.S. Food and Drug Administration approval. Gilead’s Harvoni coformulation contains sofosbuvir plus its own NS5A inhibitor, ledipasvir. Unlike ledipasvir, which is active against genotype 1, daclatasvir is more pangenotypic, meaning it works against multiple HCV genotypes.